Free Trial

Seres Therapeutics (MCRB) Competitors

Seres Therapeutics logo
$12.35 -0.03 (-0.24%)
Closing price 04:00 PM Eastern
Extended Trading
$12.21 -0.14 (-1.13%)
As of 06:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MCRB vs. RZLT, ERAS, TECX, SLDB, ITOS, ETON, ALT, CMPX, CYRX, and RVNC

Should you be buying Seres Therapeutics stock or one of its competitors? The main competitors of Seres Therapeutics include Rezolute (RZLT), Erasca (ERAS), Tectonic Therapeutic (TECX), Solid Biosciences (SLDB), iTeos Therapeutics (ITOS), Eton Pharmaceuticals (ETON), Altimmune (ALT), Compass Therapeutics (CMPX), CryoPort (CYRX), and Revance Therapeutics (RVNC). These companies are all part of the "pharmaceutical products" industry.

Seres Therapeutics vs. Its Competitors

Seres Therapeutics (NASDAQ:MCRB) and Rezolute (NASDAQ:RZLT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk, media sentiment and institutional ownership.

Seres Therapeutics has a beta of 2.75, meaning that its share price is 175% more volatile than the S&P 500. Comparatively, Rezolute has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500.

Rezolute's return on equity of -70.09% beat Seres Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Seres TherapeuticsN/A -41,084.76% -55.87%
Rezolute N/A -70.09%-63.08%

In the previous week, Rezolute had 2 more articles in the media than Seres Therapeutics. MarketBeat recorded 4 mentions for Rezolute and 2 mentions for Seres Therapeutics. Seres Therapeutics' average media sentiment score of 1.11 beat Rezolute's score of 0.34 indicating that Seres Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Seres Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Rezolute
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Seres Therapeutics has higher revenue and earnings than Rezolute. Rezolute is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Seres Therapeutics$126.32M0.85$140K-$4.60-2.68
RezoluteN/AN/A-$68.46M-$1.15-4.57

Seres Therapeutics currently has a consensus price target of $73.67, suggesting a potential upside of 496.49%. Rezolute has a consensus price target of $11.83, suggesting a potential upside of 125.40%. Given Seres Therapeutics' higher probable upside, equities research analysts plainly believe Seres Therapeutics is more favorable than Rezolute.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Seres Therapeutics
2 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.75
Rezolute
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
3.14

59.3% of Seres Therapeutics shares are owned by institutional investors. Comparatively, 83.0% of Rezolute shares are owned by institutional investors. 4.7% of Seres Therapeutics shares are owned by company insiders. Comparatively, 18.4% of Rezolute shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Rezolute beats Seres Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Seres Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for MCRB and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MCRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MCRB vs. The Competition

MetricSeres TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$108.11M$2.96B$5.56B$9.04B
Dividend YieldN/A2.42%5.25%4.03%
P/E Ratio-2.688.0519.5820.23
Price / Sales0.85296.11442.27127.79
Price / CashN/A42.7337.5058.41
Price / Book7.677.748.085.60
Net Income$140K-$54.96M$3.16B$248.43M
7 Day Performance8.76%6.04%3.77%5.15%
1 Month Performance49.52%4.47%3.90%7.62%
1 Year Performance-37.42%6.12%34.22%21.56%

Seres Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MCRB
Seres Therapeutics
3.5781 of 5 stars
$12.35
-0.2%
$73.67
+496.5%
-39.3%$108.11M$126.32M-2.68330Positive News
RZLT
Rezolute
2.6646 of 5 stars
$4.98
+3.3%
$11.83
+137.6%
+25.1%$412.20MN/A-4.3340News Coverage
High Trading Volume
ERAS
Erasca
1.8988 of 5 stars
$1.42
-1.4%
$4.57
+221.9%
-43.2%$407.93MN/A-2.29120News Coverage
Positive News
TECX
Tectonic Therapeutic
3.4935 of 5 stars
$20.78
-2.6%
$83.60
+302.3%
+35.2%$398.47MN/A-2.84120
SLDB
Solid Biosciences
3.4659 of 5 stars
$4.91
-2.4%
$15.10
+207.5%
-17.1%$389.90M$8.09M-1.64100News Coverage
ITOS
iTeos Therapeutics
3.201 of 5 stars
$10.07
-1.1%
$15.86
+57.5%
-32.3%$389.63M$35M-3.3190News Coverage
ETON
Eton Pharmaceuticals
2.6967 of 5 stars
$14.39
-0.4%
$29.67
+106.2%
+359.8%$387.51M$39.01M-79.9420News Coverage
ALT
Altimmune
2.3183 of 5 stars
$4.43
-6.9%
$19.00
+328.9%
-31.3%$386.07M$20K-3.5250News Coverage
Analyst Forecast
Gap Down
CMPX
Compass Therapeutics
2.6547 of 5 stars
$2.64
-5.0%
$12.67
+379.8%
+216.4%$384.43M$850K-6.4420
CYRX
CryoPort
2.0516 of 5 stars
$7.29
-4.8%
$10.88
+49.2%
+24.8%$384.05M$228.38M-3.121,186
RVNC
Revance Therapeutics
2.7746 of 5 stars
$3.65
flat
$8.45
+131.5%
N/A$381.02M$234.04M-1.89500

Related Companies and Tools


This page (NASDAQ:MCRB) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners